Nitinol stent implantation for femoropopliteal disease in patients on hemodialysis: results of the 3-year retrospective multicenter APOLLON study

Autor: Yoshihiro Kato, Tomonori Amano, Daisuke Nishiya, Akihiro Higashimori, Akinori Sumiyoshi, Yoshiaki Yokoi, Masahiko Fujihara, Hiromasa Taniguchi, Yusuke Iwasaki
Rok vydání: 2015
Předmět:
Male
medicine.medical_specialty
Time Factors
medicine.medical_treatment
Constriction
Pathologic
Kaplan-Meier Estimate
Femoral artery
030204 cardiovascular system & hematology
Prosthesis Design
Amputation
Surgical
Peripheral Arterial Disease
03 medical and health sciences
0302 clinical medicine
Japan
Recurrence
Renal Dialysis
Risk Factors
medicine.artery
Alloys
medicine
Humans
Vascular Patency
Popliteal Artery
030212 general & internal medicine
Renal Insufficiency
Chronic
Aged
Retrospective Studies
Aged
80 and over
Ultrasonography
Doppler
Duplex
business.industry
Endovascular Procedures
Retrospective cohort study
Middle Aged
Vascular surgery
Limb Salvage
Popliteal artery
Surgery
Cardiac surgery
Femoral Artery
Treatment Outcome
Amputation
Female
Stents
Hemodialysis
Cardiology and Cardiovascular Medicine
business
Zdroj: Heart and Vessels. 31:1476-1483
ISSN: 1615-2573
0910-8327
DOI: 10.1007/s00380-015-0740-7
Popis: The clinical outcomes of nitinol stents for femoropopliteal arterial (FP) disease in patients on hemodialysis were assessed. Endovascular therapy (EVT) is accepted for symptomatic FP disease. However, the clinical outcomes of patients on dialysis are not well known. A multicenter retrospective study was conducted with data between November 2010 and August 2013. A total of 484 consecutive patients who successfully underwent EVT for FP disease with nitinol stents were recruited and analyzed. Patients were categorized into the hemodialysis group (N = 161) and non-hemodialysis group (N = 323). The primary measure was primary patency verified by duplex ultrasound at a rest peak systolic velocity (PSVR) of >2.5, and secondary measures were freedom from target lesion revascularization (TLR) and major amputation-free survival (AFS). Average follow-up duration was 19.5 ± 13.5 months. The primary patency rate at 3 years was significantly lower in the hemodialysis group than the non-hemodialysis group (33.8 vs. 43.7 %; p = 0.036). Freedom from TLR at 3 years was 55.0 % in the hemodialysis group and 66.1 % in the non-hemodialysis group (p = 0.032). The hemodialysis group showed a significantly lower AFS rate at 3 years than the non-hemodialysis group (86.4 vs. 58.2 %; p
Databáze: OpenAIRE
Externí odkaz: